Theravance Biopharma, INC Form 4 insider transactions

Eli Samaha, a Director and 10% owner of Theravance Biopharma, Inc., reported significant purchases of company stock between June 29 and July 1, 2026.

Rhonda Farnum, SVP of Commercial & Medical Affairs at Theravance Biopharma, sold 13,314 ordinary shares via a 10b5-1 plan.

Theravance Biopharma director Laurie Smaldone Alsup was granted 6,009 ordinary shares and 13,398 stock options as part of annual compensation.

Director Susannah Gray has been granted 6,009 ordinary shares and 13,398 stock options as part of her compensation package.

Director Dean J. Mitchell has been granted 6,009 ordinary shares and 13,398 stock options as part of his compensation package.

Director Donal O'Connor was granted 6,009 ordinary shares and 13,398 stock options as part of his annual compensation package.

Director Deepika Pakianathan was granted 6,009 ordinary shares and 13,398 stock options as part of her compensation for service on the board.

Theravance Biopharma CEO Rick Winningham withheld 20,038 shares to satisfy tax obligations related to restricted stock unit vesting.

CFO Aziz Sawaf disposed of 8,670 shares of Theravance Biopharma to satisfy tax obligations related to RSU vesting.

Aine Miller, SVP of Development at Theravance Biopharma, reported the withholding of 6,827 shares to satisfy tax obligations related to RSU vesting.

SVP and General Counsel Brett A. Grimaud disposed of 8,829 shares to satisfy tax obligations related to restricted stock unit vesting.

Rhonda Farnum, SVP of Theravance Biopharma, reported the withholding of 5,678 shares to satisfy tax obligations related to RSU vesting.

Rick E. Winningham, CEO of Theravance Biopharma, Inc., reported transactions involving ordinary shares, including the acquisition of 75,000 shares.

Aziz Sawaf, SVP & CFO of Theravance Biopharma, acquired 37,500 ordinary shares through a Rule 10b5-1(c) plan.

Brett A. Grimaud, SVP, General Counsel and Secretary of Theravance Biopharma, Inc., acquired 37,500 ordinary shares.

Rhonda Farnum, SVP of Commercial & Medical Affairs at Theravance Biopharma, acquired 18,750 ordinary shares.

Theravance Biopharma's SVP of Communications and Medical Affairs, Rhonda Farnum, sold ordinary shares totaling 31,067 units on March 16, 2026, under a pre-arranged 10b5-1 plan.

Theravance Biopharma CEO Rick E Winningham disposed of 74,975 ordinary shares to cover tax obligations arising from vested restricted stock units.

Theravance Biopharma's SVP & CFO, Aziz Sawaf, disposed of 20,672 ordinary shares to cover tax obligations from vested restricted stock units.

Aine Miller, SVP at Theravance Biopharma, disposed of 16,851 ordinary shares to cover tax liabilities from vested restricted stock units.

Theravance Biopharma's SVP, General Counsel, and Secretary, Brett A. Grimaud, reported a routine disposition of shares to cover tax obligations from vested restricted stock units.

Rhonda Farnum, SVP of Commercial and Medical Affairs at Theravance Biopharma, Inc., reported a routine disposition of shares to cover tax obligations related to vested restricted stock units.

Theravance Biopharma's SVP of Communications and Medical Affairs, Rhonda Farnum, sold 31,067 ordinary shares for approximately $18.75 per share under a pre-arranged 10b5-1 plan.

Eran Broshy, a director at Theravance Biopharma, sold 29,501 ordinary shares for approximately $590,020 on November 26, 2025, under a pre-arranged 10b5-1 trading plan.

Theravance Biopharma's SVP & CFO, Aziz Sawaf, disposed of 18,627 ordinary shares to cover tax liabilities from vested restricted stock units.

Aine Miller, SVP, Development & Head of IRE Office at Theravance Biopharma, disposed of 6,989 ordinary shares to satisfy tax obligations from restricted stock unit vesting.

Theravance Biopharma's SVP, General Counsel, and Secretary, Brett A. Grimaud, disposed of shares to cover tax obligations from vested restricted stock units.

Theravance Biopharma's SVP of Communications and Medical Affairs, Rhonda Farnum, disposed of 9,060 ordinary shares to cover tax obligations related to vested restricted stock units.

Theravance Biopharma CEO Rick Winningham disclosed recent share transactions, including gifts to a custodial account and shares withheld for tax obligations.

Theravance Biopharma Director Eran Broshy filed an amended Form 4 to correct the number of shares sold on November 11, 2025, under a Rule 10b5-1 trading plan.